Biomedical Research · 2009 · 16 citations · 15 references
MedicineHematologyOncologyCancer ImmunologyImmunopathologyTumor ImmunologyCancer ImmunotherapyCytokines In Tumor ImmunityImmuno-oncology BiomarkersImmunological Disease ModelsHemoglobin LevelsImmuno-oncology ModelsInoculationInterleukin-6 Mediated Regulation
We established models of cancer-related anemia in mice from subcutaneous inoculation of two IL-6-producing cancer cell lines, human lung cancer cell line LC-06-JCK and murine colon26 clone 5 colon cancer cells. In both models, elevated levels of IL-6 were detected in sera and hemoglobin levels significantly decreased compared with non-tumor-bearing mice. In the LC-06-JCK model, serum albumin levels also decreased with elevated levels of human IL-6 in sera. On the other hand, serum levels of EPO increased, although anemia developed and did not improve. The development of cancer-related anemia was prevented by the administration of a rat anti-mouse IL-6 receptor antibody, MR16-1, in the LC-06-JCK model. It is therefore suggested that IL-6 causes anemia independent of a reduction in EPO levels. Our preclinical models should be useful for exploring new modalities for the treatment of cancer-related anemia.
15
Hepcidin, a putative mediator of anemia of inflammation, is a type II acute-phase protein
Elizabeta Nemeth, Erika V. Valore, Mary Territo et al. · Blood · 2003 · 1.4K citations · Full text
Medicine, Hematology, Immunology +14
Heinz Ludwig, Simon Van Belle, Peter Barrett‐Lee et al. · European Journal of Cancer · 2004 · 928 citations
Medicine, Hematology, Oncology +10
Circulating interleukin‐6 predicts survival in patients with metastatic breast cancer
Roberto Salgado, Sara Junius, Ina Benoy et al. · International Journal of Cancer · 2002 · 436 citations · Full text
Medicine, Immunology, Oncology +14